ResMed (NYSE: RMD) reports Q3 EPS of $0.39 (ex-items), 3 cents worse than estimates.(0.42) Revenues were $183 million vs ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE